Literature DB >> 2043580

Yellow mercuric oxide: a treatment of choice for phthiriasis palpebrarum.

I Ashkenazi1, H R Desatnik, F A Abraham.   

Abstract

Thirty-five patients presenting with phthiriasis palpebrarum were all treated with a regimen of 1% yellow oxide of mercury ointment four times daily for 14 days. At the conclusion of treatment there was complete resolution of the signs and symptoms of the disease. No side effects due to the treatment were reported or detected. We have shown that 1% mercuric oxide ointment is both a safe and effective treatment for phthiriasis palpebrarum. We recommend it as the treatment of choice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2043580      PMCID: PMC1042383          DOI: 10.1136/bjo.75.6.356

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  8 in total

1.  Phthiriasis palpebrarum (phthiriasis ciliaris).

Authors:  H H PERLMAN; S FRAGA; M MEDINA
Journal:  J Pediatr       Date:  1956-07       Impact factor: 4.406

2.  Treatment of pediculosis ciliorum in an infant.

Authors:  F RONCHESE
Journal:  N Engl J Med       Date:  1953-11-26       Impact factor: 91.245

3.  DEPOSITION OF MERCURY IN THE EYE.

Authors:  I Abramowicz
Journal:  Br J Ophthalmol       Date:  1946-11       Impact factor: 4.638

4.  Argon laser phototherapy of phthiriasis palpebrarum.

Authors:  K J Awan
Journal:  Ophthalmic Surg       Date:  1986-12

5.  Placebo-controlled, double-blind evaluation of the efficacy and safety of yellow mercuric oxide in suppression of eyelid infections.

Authors:  P R Kastl; Z Ali; F Mather
Journal:  Ann Ophthalmol       Date:  1987-10

6.  [Keratoconjunctivitis following pediculocides].

Authors:  D Ben-Ezra; J H Paez; C Almeida; J Pe'er; A Zelikovitch; I Barzel
Journal:  Harefuah       Date:  1983-02-01

7.  Cryotherapy in phthiriasis palpebrarum.

Authors:  K J Awan
Journal:  Am J Ophthalmol       Date:  1977-06       Impact factor: 5.258

8.  Diagnosing and treating Phthirus pubis palpebrarum.

Authors:  J M Couch; W R Green; L W Hirst; Z C de la Cruz
Journal:  Surv Ophthalmol       Date:  1982 Jan-Feb       Impact factor: 6.048

  8 in total
  8 in total

1.  Chronic conjunctivitis related to phthiriasis palpebrarum.

Authors:  Rodrigo de Pinho Paes Barreto; Ana Luiza Biancardi; Marcio José Salgueiro
Journal:  Int Ophthalmol       Date:  2012-06-16       Impact factor: 2.031

2.  Phthirus pubis infestation of the eyelids.

Authors:  P A Rundle; D S Hughes
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

3.  Phthriasis palpebrarum mimicking lid eczema and blepharitis.

Authors:  Burak Turgut; Julide Kurt; Onur Catak; Tamer Demir
Journal:  J Ophthalmol       Date:  2009-11-30       Impact factor: 1.909

4.  Crab lice infestation in unilateral eyelashes and adjacent eyelids: A case report.

Authors:  Wei Tang; Qian-Qian Li
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

5.  Phthirus pubis Infestation of the Eyelids Presenting as Chronic Blepharoconjunctivitis in a 6-Year-Old Girl: A Case Report.

Authors:  Viola Andin Dohvoma; Steve Robert Ebana Mvogo; Paul Jean Adrien Atangana; Pamela Nyasse; Emilienne Epee; Côme Ebana Mvogo
Journal:  Case Rep Ophthalmol       Date:  2018-01-10

6.  Combined treatment modality including topical 20% fluorescein dye in the management of phthiriasis palpebrarum - A case series.

Authors:  Chitaranjan Mishra; Usha Kim; Mulasthanam S Dheera; Krishin Krishnakumar
Journal:  Indian J Ophthalmol       Date:  2022-04       Impact factor: 2.969

7.  Treatment of Phthiriasis Palpebrarum and Crab Louse: Petrolatum Jelly and 1% Permethrin Shampoo.

Authors:  Yunus Karabela; Gurkan Yardimci; Isik Yildirim; Eray Atalay; Semsi Nur Karabela
Journal:  Case Rep Med       Date:  2015-09-15

8.  Phthiriasis palpebrarum in three young siblings.

Authors:  Eleni Papageorgiou; Sotirios Kalampalikis; Petros Koltsidopoulos; Evangelia Tsironi
Journal:  Oxf Med Case Reports       Date:  2018-10-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.